Evidence map›Paper›PMID 27012560›Full record

ArticleThe Journal of investigative dermatology2016

Venturing into the New Science of Nucleases.

Markéta Tolarová, John A McGrath, Jakub Tolar

Open access · greenAbstract readComment
PubMed Full text at PMC Publisher
In one paragraph

Article in The Journal of investigative dermatology, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.3field-weighted citation impact, top 32% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 3 citations in OpenAlex.

  1. Review
  2. Review
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

3 authors at 3 institutions in 3 countries.

Markéta TolarováUniverzita Karlova v Praze 2 lekarska fakulta, Medicine, Prague, Czech Republic.
John A McGrathGenetic Skin Disease Group, St. John's Institute of Dermatology, London, UK.
Jakub TolarDepartment of Pediatrics, University of Minnesota, Minneapolis, Minnesota, USA. Electronic address: tolar003@umn.edu.
Charles University · CZSt John's Hospital · GBUniversity of Minnesota · US

Funding

Women's CancerP30CA077598 · NCI · UNIVERSITY OF MINNESOTA TWIN CITIES · PI Douglas Yee · 1998 to 2026
$100.4M
Skin-targeted Cell Therapy for Recessive Dystrophic Epidermolysis BullosaR01AR063070 · NIAMS · UNIVERSITY OF MINNESOTA · PI Mark J Osborn, Jakub Tolar · 2013 to 2026
$4.5M
NCI NIH HHS P30 CA077598NIAMS NIH HHS R01 AR063070
6 · The paper itself

Abstract

Gene editing with zinc finger nucleases, transcription activator-like effector nucleases, clustered regularly interspaced palindromic repeats (CRISPR)/CRISPR-associated proteins system, or meganucleases can, in principle, mediate any genome modification. Recent studies have shown that COL7A1 mutations in cells of patients with recessive dystrophic epidermolysis bullosa can be corrected by homology-directed DNA repair.

Indexed as

DNA RepairCollagen Type VIIEpidermolysis Bullosa DystrophicaHumansCollagen Type VII

Identifiers

PMID27012560
PMCPMC5320895
OpenAlexW2299389515

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.